编者按：2016年4月8日，由中国眼科学国家重点实验室、中山大学眼科中心、中山大学、Nature Materials和Nature Reviews Materials 共同承办的自然学术会议“Tissue Engineering and Regenerative Medicine”在广州远洋宾馆顺利举办。大会邀请了20余名国内外专家对当前组织医学与再生医学的最新进展及面临的挑战进行精彩的报告。
在此次会议中，美国约翰霍普金斯医学院Jennifer Elisseeff教授作了主题为“Translational Biomaterials in Regenerative Medicine and the Resulting Impact”的精彩演讲。笔者在会后也有幸邀请到Elisseeff教授做一个简单的访谈，与大家分享Elisseeff教授对转化生物材料对再生医学的作用及影响的看法。
图：Prof. Jennifer Elisseeff接受AME编辑采访
1. What do you think about the significance of tissue regeneration to ophthalmology?
2. What is the most challenging issue in the field of tissue engineering?
3. You are now examining hydrogels as a scaffold for tissue engineering, any advances on this project?
4. Any plan on translational biomaterials in regenerative medicine in the future?
5. What effect do you hope to achieve?
Jennifer Elisseeff is a professor of ophthalmology and orthopaedic surgery at the Johns Hopkins School of Medicine. She also holds appointments in the Johns Hopkins Department of Chemical and Biological Engineering and Department of Materials Science and Engineering. Her research focuses on tissue regeneration. Dr. Elisseeff is the Jules Stein Professor of Ophthalmology and director of the Translational Tissue Engineering Center. Her team is engaged in engineering technologies to repair lost tissues. Specifically, she is examining hydrogels as a scaffold for tissue engineering and is working to develop an artificial cornea.